Vaccination against the Epstein-Barr virus
Epstein–Barr virus (EBV) was the first human tumor virus being discovered and remains to date the only human pathogen that can transform cells in vitro. 55 years of EBV research have now brought us to the brink of an EBV vaccine. For this purpose, recombinant viral vectors and their heterologous pri...
Autors principals: | Rühl, J, Leung, CS, Münz, C |
---|---|
Format: | Journal article |
Idioma: | English |
Publicat: |
Springer Nature
2020
|
Ítems similars
-
Redirecting T Cells against Epstein–Barr Virus Infection and Associated Oncogenesis
per: Christian Münz
Publicat: (2020-06-01) -
Epstein–Barr Virus-Specific Immune Control by Innate Lymphocytes
per: Christian Münz
Publicat: (2017-11-01) -
Immune Escape by Non-coding RNAs of the Epstein Barr Virus
per: Christian Münz
Publicat: (2021-06-01) -
Co-Stimulatory Molecules during Immune Control of Epstein Barr Virus Infection
per: Christian Münz
Publicat: (2021-12-01) -
Vaccination against Epstein–Barr Latent Membrane Protein 1 Protects against an Epstein–Barr Virus-Associated B Cell Model of Lymphoma
per: Wesley I. Soo Hoo, et al.
Publicat: (2023-07-01)